Submitted: 29 Oct 2018
Accepted: 03 Mar 2019
First published online: 28 Feb 2019
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)

J Prev Epidemiol. 2019;4(1):e03-e03.
  Abstract View: 57
  PDF Download: 52

Original

Lens opacity as a serious side effect following chelation therapy in beta thalassemia: A comparison between deferoxamine and deferasirox; randomized double-blinded clinical trial

Mohammad Reza Golpayegani 1 ORCiD, Vahid Falahati 2 * ORCiD, Sam Habibollahi Habibollahi 3, Mahsa Fallahi 4

1 Pediatric Oncology and Hematology, Kermanshah University of Medical Sciences, Tehran, Iran
2 Oncology and Hematology Department, Arak University of Medical Sciences, Arak, Iran
3 Farabi Hospital, Tehran University of Medical Sciences, Tehran, Iran
4 Hospital, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Introduction: Ocular toxicity is a serious side effect following chelation therapy in patients suffering from major beta-thalassemia.

Objectives: We aimed to assess ocular toxicity (lens opacity) of the Iranian brand of deferasirox named "Osveral" marketed by an Iranian company and also to compare it with deferoxamine.

Patients and Methods: This randomized double-blinded clinical trial was performed on 50 major betathalassemia patients who were candidate for chelation therapy for the first time. Patients were randomly (using a computerized random number table) assigned to receive deferoxamine (50 mg/kg subcutaneous daily, 5 days per week, for 24 months) (25 patients) or Osveral (30 mg/kg orally for 24 months) (25 patients). After a year, patients were reassessed with regard to the appearance of lens opacity.

Results: In the group receiving deferoxamine, 4 patients (16.0%) suffered from mild opacity, 1 (4%) from moderate opacity and 2 (8%) from severe opacity, while in the group receiving Osveral, only 4 patients (16%) had mild lens opacity indicating no significant difference across the two groups (P = 0.456).

Conclusion: The rate of lens opacity appeared following administration of deferasirox and desferrioxamine is similar and in the range globally reported.

Citation: Golpayegani MR, Falahati V, abibollahi S, Fallahi M. Lens opacity as a serious side effect following chelation therapy in beta thalassemia: A comparison between deferoxamine and deferasirox; randomized double-blinded clinical trial. J Prev Epidemiol. 2019;4(1):e03. 
First name
 
Last name
 
Email address
 
Comments
 
Security code